Compare MobilEye Global Inc (MBLY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Zimmer Biomet Holdings Inc — how do they compare? MobilEye Global Inc trades at $7.1 (market cap $6.00B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.8× MobilEye Global Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MBLY | ZBH | |
|---|---|---|
Market Cap | $6.00B | $16.95B |
Volume | 7,007,849 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $103.98 |
52-Week Low | $6.56 | $79.58 |
Typical Hold Time | 15 Days | 89 Days |
Enterprise Value | $4.56B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.10, down 0.7% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong revenue growth to $2.0B in 2026 but deep net losses widening to -$4.1B. Analyst consensus leans bullish with 57.7% buy ratings and $10.83 price target, though technical indicators show selling pressure with RSI near oversold levels at 29.04. Recent news highlights ADAS business momentum and autonomous vehicle expansion initiatives.
MBLY presents a high-risk opportunity with significant upside potential if execution improves, but current profitability challenges and bearish technicals warrant caution. The 42% discount to book value and institutional accumulation offer value appeal, though sustained losses and competitive pressures in autonomous driving create substantial execution risk for investors.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
